Philippe GUÉDAT

Dr Philippe Guédat has over 20 years of experience in drug discovery in the industry. Philippe held positions of responsibility in the “business units” he was in charge of: he was the Director of Chemistry at Hybrigenics and the head of the drug discovery department at Vivalis (now Valneva). His expertise ranges from the discovery of chemical molecules with the implementation of high-throughput screening platforms to clinical development of drug candidates. Philippe has a Master’s degree in medicinal chemistry and pharmacology, a Master’s degree of supramolecular organic chemistry and a PhD in medicinal chemistry and pharmacology from the University Louis Pasteur (Strasbourg). Philippe worked at the University of Cambridge (UK), SmithKline Beecham (UK), Merck-Serono, Hybrigenics and Vivalis (now Valneva). In 2013, he founded InFlectis BioScience where is acting as Chairman and Chief Executive Officer since inception.


Jérôme Guéret has a deep experience in venture capital industry and financing. Since 2013, Jérôme is partner at GO Capital, one of the leading high tech venture capital in France. Before joining GO Capital, Jérôme was CEO of a high tech electronic company sold to EDF-EN Group in 2008 and was former television VP marketing at Orange Group in 2003. He managed projects and drove strategic execution on new business lines and emerging markets, specifically in telecom and energy sectors. Jerome has a degree from Kedge Business School and an Executive MBA from ESCP Europe.




Emilie Lidome has a biological engineering & management of enterprise background, and joined the venture capital field in 2008. Investment Director at CM-CIC Capital Innovation, a subsidiary of the Crédit Mutuel – CIC group’s investment and merchant bank division, she invests in high technology companies. Before joining CM-CIC Capital Innovation, she worked in the biotechnology & pharmaceutical industries. She led fundamental research projects and has carried out missions of departments’ coordination consulting in companies such as Novartis or GSK. Emilie Lidome has a degree in biological engineering from the Université de Technologie de Compiegne and holds a Master’s Degree in Management of Biotechnology Companies from Grenoble Ecole de Management.


Dr Pierre Miniou has over 15 years of international experience in business development and licensing in the biopharmaceutical industry with the signing of many partnering and license agreements. He has experience of senior management in having been the head of the patent department of Pierre Fabre Laboratories and a member of the Executive Committee of Vivalis (now Valneva) and Director of Vivalis Toyama (Japan). Pierre holds a Master’s degree and Engineering degree in Biotechnology of the School of Biotechnology of Strasbourg and a PhD in Molecular and Cellular Biology of the Louis Pasteur University of Strasbourg. He is also graduated of the CEIPI (Centre for International Studies of Industrial Property) in Strasbourg and has a MBA (Audencia, Nantes). He worked as a researcher at Transgene (Strasbourg), the Wistar Institute (Philadelphia, PA), the Necker Hospital (Paris) and the IGBMC (Strasbourg). He then left the laboratory activities to join the law firm Cabinet Regimbeau (Paris) prior to join Pierre Fabre Laboratories. In 2013, he founded InFlectis BioScience.

Chrisptophe PASIK

Christophe Pasik is the co-founder and past CEO of Keocyt SAS a French pharmaceutical company (2006-2017). He is an active Business Angel, co-founder of several healthcare societies and Board Member of several French Biotech and Healthcare companies. From 1990 to 2006, he held various positions in Pharma companies such as Pfizer, Pharmacia, Catalent and Merck Lipha in France and abroad.